Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Improvement in pneumon.. 57% Improvement Relative Risk HCQ  Chen et al.  LATE TREATMENT  RCT Is late treatment with HCQ beneficial for COVID-19? RCT 62 patients in China (February - February 2020) Lower pneumonia with HCQ (p=0.042) Chen et al., medRxiv doi:10.1101/2020..., Mar 2020 Favors HCQ Favors control

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Chen et al., medRxiv doi:10.1101/2020.03.22.20040758
Mar 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
62 patients. RCT showing significantly faster recovery with HCQ. 13% progressed to severe cases in the control group, versus 0% for the treatment group. Significant improvement seen in pneumonia on chest CT for 61% of treated patients and 16% of control patients.
risk of no improvement in pneumonia at day 6, 57.0% lower, RR 0.43, p = 0.04, treatment 6 of 31 (19.4%), control 14 of 31 (45.2%), NNT 3.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 31 Mar 2020, Randomized Controlled Trial, China, preprint, 9 authors, study period 4 February, 2020 - 28 February, 2020.
This PaperHCQAll
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough .
Ethics approval and consent to participate The clinical research protocol was reviewed and approved by the Ethics Committee in Renmin Hospital of Wuhan University (Wuhan, China). All research procedures adhered to the tenets of the Declaration of Helsinki. This trial has been registered in the Chinese Clinical Trial Registry, the unique identifier: ChiCTR2000029559. Conflict of Interest Disclosures All authors declare no competing interests. Author Contributions ZZ designed this study and major in the clinical management of patients, data collection, data analysis, and writing of the first draft. ZC and JH improved the data analysis and finished the manuscript. SJ helped the clinical management of patients. SH had roles in data collection and interpretation. ZZ and DY had roles in data analysis and data interpretation, RZ and BH helped the data collection. All authors reviewed and approved the final version of the manuscript.
Akpovwa, Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity, Cell Biochem Funct, doi:10.1002/cbf.3182
Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet, doi:10.1016/S0140-6736(20)30211-7
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Conti, Ronconi, Caraffa, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Gorbalenya, Baker, Baric, Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group, bioRxiv
Gordon, Amissah-Arthur, Gayed, The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology, doi:10.1093/rheumatology/kex286
Keyaerts, Vijgen, Maes, Neyts, Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun, doi:10.1016/j.bbrc.2004.08.085
Li, Guan, Wu, Early Transmission Dynamics in Wuhan, China, of Novel . Coronavirus-Infected Pneumonia, The New England journal of medicine, doi:10.1101/2020.02.07.937862
Liu, Li, Liu, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, medRxiv, doi:10.1101/2020.02.16.20023671
Ma, Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases, J Antimicrob Chemother, doi:10.1093/jac/dkv018
Proano, Glenn, Hydroxychloroquine Retinal Toxicity, N. Engl. J. Med, doi:10.1056/NEJMicm1304542
Radke, Kingery, Maakestad, Krasowski, Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report, Toxicol Rep, doi:10.1016/j.toxrep.2019.10.006
Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology, doi:10.1007/s10787-015-0239-y
Schrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: . implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Horby, Hayden, Gao, A novel coronavirus outbreak of global health concern, The Lancet, doi:10.1016/S0140-6736(20)30185-9
Zhu, Zhang, Wang, A Novel Coronavirus from Patients with Pneumonia in China, 2019, New Engl J Med, doi:10.1056/NEJMoa2001017
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop